Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing medicines for areas of high unmet need [2] - The company currently has two programs in the clinic, with the most advanced being Cemsidomide, an IKZF1/3 degrader targeting multiple myeloma [2] Clinical Development - C4 Therapeutics completed a Phase I study for Cemsidomide last year and has initiated a Phase II study called MOMENTUM, which began dosing patients last month [2] - The company plans to start a Phase Ib study in Q2 in combination with elranatamab, a BiTE from Pfizer, indicating a differentiated registrational path for its development [3]

Core Insights - C4 Therapeutics is advancing its investigational drug cemsidomide into later-stage clinical trials for multiple myeloma, with the first patient dosed in the Phase 2 MOMENTUM trial, which is designed for potential accelerated approval [1][2][12] - The company reported a strong financial position with cash, cash equivalents, and marketable securities totaling $297.1 million as of December 31, 2025, providing a runway to fund operations until the end of 2028 [1][10] - C4 Therapeutics is also focusing on expanding its research and discovery efforts in inflammation, neuroinflammation, and neurodegeneration, while maintaining collaborations in oncology [2][5] Financial Performance - Total revenue for the fourth quarter and full year ended December 31, 2025, was $11.0 million and $35.9 million, respectively, compared to $5.2 million and $35.6 million for the prior year periods, indicating a significant increase in quarterly revenue [6] - Research and development (R&D) expenses for the fourth quarter and full year were $25.0 million and $104.2 million, respectively, down from $32.5 million and $110.6 million in the prior year, primarily due to the completion of a clinical trial [7] - General and administrative (G&A) expenses for the fourth quarter and full year were $9.2 million and $36.2 million, respectively, compared to $10.4 million and $42.1 million in the prior year, reflecting a decrease in stock-based compensation [8] - The net loss for the fourth quarter and full year was $20.5 million and $105.0 million, respectively, compared to $34.6 million and $105.3 million for the prior year periods, with net loss per share improving to $0.18 and $1.27 [9] Clinical Development Updates - The Phase 2 MOMENTUM trial aims to evaluate cemsidomide in combination with dexamethasone in patients with relapsed/refractory multiple myeloma, with an expected enrollment of approximately 100 patients by Q1 2027 [5][12] - A Phase 1b trial of cemsidomide in combination with elranatamab is set to initiate in Q2 2026, following a collaboration agreement with Pfizer [5][13] - C4 Therapeutics plans to present further analysis of data from the completed Phase 1 trial of cemsidomide in mid-2026 and initiate an additional Phase 1b trial to evaluate cemsidomide with other anti-myeloma agents [5][14] Strategic Focus - The company is committed to advancing its discovery strategy, targeting areas with strong degrader rationale and first-in-class potential, particularly in inflammation and neurodegeneration [2][5] - C4 Therapeutics aims to optimize indication selection across its discovery portfolio and deliver at least one development candidate to a collaboration partner by the end of 2026 [14]

Core Insights - C4 Therapeutics has initiated the Phase 2 MOMENTUM trial for cemsidomide in combination with dexamethasone, targeting relapsed/refractory multiple myeloma patients, with enrollment expected to complete by Q1 2027 [1][7] - The Phase 1b trial of cemsidomide in combination with elranatamab is set to begin in Q2 2026, supporting a regulatory strategy for accelerated approvals in multiple myeloma [2][3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation science, aiming to develop innovative therapies for difficult-to-treat diseases [10] - The company's lead candidate, cemsidomide, is an investigational oral IKZF1/3 degrader, showing promising safety and efficacy profiles in prior trials [4][10] Trial Details - The Phase 2 MOMENTUM trial is an open-label, single-arm study enrolling approximately 100 patients, evaluating cemsidomide at a dose of 100 µg, administered in a 14 days on and 14 days off schedule [2][5] - The primary endpoint of the trial is the overall response rate as per International Myeloma Working Group criteria, assessed by an independent review committee [5][9] Upcoming Milestones - Further analysis of the completed Phase 1 trial of cemsidomide in combination with dexamethasone is anticipated in mid-2026 [7] - The Phase 1b trial of cemsidomide with elranatamab will explore safety and preliminary efficacy, contributing to the broader development strategy for cemsidomide [6][3] Industry Context - Multiple myeloma is a rare blood cancer with approximately 36,000 new diagnoses annually in the U.S., highlighting the need for new therapeutic options as most patients eventually relapse [9] - IKZF1/3 degraders are foundational therapies in multiple myeloma treatment, and cemsidomide aims to enhance treatment efficacy and patient outcomes [9]

Core Insights - Analysts maintain a bullish outlook on C4 Therapeutics (CCCC), with a consensus price target of $7.00, indicating a potential upside of 270.37% driven by confidence in Cemsidomide, the company's primary degrader [1] Group 1: Clinical and Regulatory Milestones - C4 Therapeutics has outlined key clinical and regulatory milestones through 2028, aiming for accelerated approval of Cemsidomide for relapsed/refractory multiple myeloma [2] - The company plans to submit a New Drug Application (NDA) by the end of 2028, with initial Overall Response Rate (ORR) data expected in the second half of 2027 [3] - A Phase 2 MOMENTUM trial for fourth-line or later patients is set to launch in Q1 2026, while a Phase 1b combination study with elranatamab is scheduled for Q2 2026, and a Phase 3 trial is anticipated by early 2028 [3] Group 2: Clinical Data and Partnerships - Based on 2025 Phase 1 data, Cemsidomide demonstrated ORRs of 40% at 75 µg and 53% at 100 µg [4] - C4 Therapeutics has established partnerships with Merck KGaA, Roche, and Biogen, with plans to file up to three Investigational New Drug (IND) applications by 2028 across its neuro- and inflammation programs, in addition to oncology [4] Group 3: Company Overview - C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes its Degronimid platform to develop small-molecule degraders aimed at selectively eliminating disease-driving proteins in neurodegenerative, inflammatory, and cancerous diseases [5]

Core Insights - C4 Therapeutics is advancing cemsidomide as a foundational medicine for multiple myeloma, with trials set to initiate in 2026 [2][11] - The company is focusing on a new discovery strategy targeting inflammation and neuro-degenerative diseases, leveraging its expertise in targeted protein degradation [2][13] - C4 Therapeutics has a strong financial position, with a cash runway extending to the end of 2028, allowing for continued development through key milestones [2][12] Group 1: Cemsidomide Development - The Phase 2 MOMENTUM trial of cemsidomide is scheduled to begin in Q1 2026, with a recommended dose of 100 µg [1][11] - The Phase 1b trial in combination with elranatamab is set to start in Q2 2026, with ongoing updates expected throughout the trial [1][14] - Initial overall response rate data from the MOMENTUM trial is anticipated in 2H 2027, with efficacy and safety data to follow in mid-2028 [6][11] Group 2: Early Portfolio and Discovery Strategy - C4 Therapeutics aims to deliver up to three investigational new drug applications by the end of 2028, focusing on inflammation and neuro-degenerative diseases [7][13] - The company is utilizing data from the Phase 1 trial of CFT8919 to inform clinical development outside of China [5] - The internal discovery strategy is designed to develop degrader medicines targeting novel pathways, enhancing efficacy for patients with unmet needs [13] Group 3: Financial Position and Strategic Milestones - C4 Therapeutics has completed enrollment in the Phase 1 trial of cemsidomide and dexamethasone, showing promising overall response rates of 40% and 53% at the highest doses [12] - The company has developed a regulatory path for potential accelerated approvals for cemsidomide in multiple treatment lines [12] - Collaborations with major pharmaceutical companies are expected to yield additional research milestones and potential licensing fees [12]

Summary of C4 Therapeutics FY Conference Call Company Overview - C4 Therapeutics is a targeted protein degradation company focused on developing breakthrough medicines for patients with high unmet medical needs [3][4] - The company has two active clinical programs: - Cemsidomide (IKZF1/3 degrader) with data recently presented at IMS in Toronto, expected to enter the next phase of development early next year [3][4] - CFT8919 (EGFR L858R degrader) currently in a phase one first-in-human study in collaboration with Betta Pharmaceuticals in China [3][4] Clinical Program Updates - **Cemsidomide**: - Phase 1 dose escalation study showed an overall objective response rate (ORR) of 36% across 72 patients, with higher doses (75 micrograms and 100 micrograms) achieving ORRs of 40% and 53% respectively [6][7] - Median duration of treatment was 9.3 months, with a safety profile indicating only 6% of patients had dose reductions due to safety reasons [7][8] - 100% of patients were triple-class exposed, with 75% having prior CAR T or T cell engager therapy, showing consistent response rates across these subgroups [8][14] - **Comparison with Mezigdomide**: - Cemsidomide's response rate (53%) is competitive with mezigdomide (55%), but with a significantly better safety profile, as mezigdomide had higher rates of discontinuations and dose reductions due to safety [13][14] Future Development Plans - The company plans to advance Cemsidomide to the next phase of studies, with a meeting scheduled with the FDA to align on dosing [16][18] - The expected ORR for the upcoming 4L+ study is around 40%, based on a background rate of 20% [20] Financial and Strategic Considerations - C4 Therapeutics has a cash runway through the end of 2028, which does not include potential milestone payments of up to $40 million from collaboration partners [32] - The company is focused on moving Cemsidomide to the next phase while also supporting the ongoing study with Betta Pharmaceuticals [31][32] Commercial Considerations - Pricing for Cemsidomide is still under consideration, with the goal to be competitive based on the value it brings to patients [21] - The expected duration of response in a last-line setting is anticipated to be over six months, with current data showing 9.3 months [23] Combination Therapy Insights - C4 Therapeutics is exploring the combination of Cemsidomide with bispecific T-cell engagers, with evidence suggesting potential synergistic effects [24][25] - The study design will introduce Cemsidomide only after patients reach the loaded dose of the BiTE, with careful monitoring of safety and tolerability [26][27] Key Takeaways - C4 Therapeutics is making significant progress in its clinical programs, particularly with Cemsidomide, which shows promising efficacy and safety profiles compared to competitors - The company is strategically positioned for future growth with a solid financial runway and ongoing collaborations, while also preparing for potential commercial opportunities in the near future

Core Insights - C4 Therapeutics, Inc. (C4T) will present data from its Phase 1 clinical trial of cemsidomide for multiple myeloma at the International Myeloma Society Annual Meeting on September 20, 2025 [1][2] - The company has completed enrollment and dose escalation for the trial, which shows a well-tolerated safety profile and promising response rates [2] - An investor webcast will follow the oral presentation, providing further details on the clinical development plans [3] Company Overview - C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation to develop new medicines [4] - The company utilizes its TORPEDO platform to design and optimize small-molecule medicines for challenging diseases [4] - C4T's degrader medicines aim to leverage the body's natural protein recycling system to eliminate disease-causing proteins, potentially addressing drug resistance and improving patient outcomes [4] Product Information - Cemsidomide is an investigational small-molecule degrader that targets IKZF1/3, which are transcription factors involved in multiple myeloma and non-Hodgkin's lymphomas [5] - Clinical data indicates that cemsidomide is well-tolerated and shows significant anti-myeloma activity along with immunomodulatory effects [5]

Core Insights - C4 Therapeutics, Inc. reported compelling overall response rates for cemsidomide in multiple myeloma, with a 50% overall response rate (ORR) at the highest dose of 100 µg, including one patient achieving a minimal residual disease negative complete response [1][5] - The company plans to prioritize the development of cemsidomide and expects FDA feedback by mid-2025 to support the next phase of development in early 2026 [1][2] - C4T's financial position remains strong, with cash, cash equivalents, and marketable securities totaling $234.7 million as of March 31, 2025, expected to fund operations into 2027 [1][15] Cemsidomide Development - Cemsidomide's Phase 1 trial in multiple myeloma has shown a 50% ORR at the 100 µg dose level, with 80% of patients having prior CAR-T or T-cell engager therapy [5] - At the 75 µg dose level, an ORR of 40% was achieved [5] - The drug is well-tolerated with manageable neutropenia, and the ongoing Phase 1 trial for non-Hodgkin's lymphoma is still in progress [5] Financial Performance - Total revenue for Q1 2025 was $7.2 million, up from $3.0 million in Q1 2024, primarily due to collaborations with Merck KGaA and Roche [9] - Research and development expenses increased to $27.1 million in Q1 2025 from $22.5 million in Q1 2024, reflecting higher clinical trial costs [10] - General and administrative expenses decreased to $9.3 million in Q1 2025 from $10.3 million in Q1 2024 due to reduced personnel costs [11] Strategic Decisions - The company has decided not to advance CFT1946 beyond the current Phase 1 trial and will seek partnership opportunities for the BRAF program [14][18] - C4T continues to advance its internal research pipeline, focusing on targets with a strong degrader rationale applicable to various therapeutic areas [14] Upcoming Milestones - C4T plans to present data from the completed cemsidomide Phase 1 dose escalation in multiple myeloma in Q3 2025 and in non-Hodgkin's lymphoma in Q4 2025 [14] - The company aims to initiate the next phase of clinical development for cemsidomide in early 2026 [14]